Type 1 Diabetes Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
Phase 1 (up to 50 people):
- People aged 18–45 with type 1 diabetes who have severe complications, including advanced eye disease (proliferative retinopathy), large amounts of protein in the urine (macroalbuminuria), moderate-to-severe kidney disease (CKD class 3B or worse), and severe nerve damage, with or without foot ulcers. If enough participants in this age range cannot be found, the age range may be extended to 18–60 years.
Phase 2 (up to 250 people):
- People aged 18–45 with type 1 diabetes and no diabetes-related small blood vessel complications, or only very early and potentially reversible eye changes (Group a)
- People aged 18–45 with type 1 diabetes and mild-to-moderate early eye disease, small amounts of protein in the urine, and/or early signs of nerve damage (Group b)
- People aged 18–45 with type 1 diabetes and moderate eye disease, larger amounts of protein in the urine or kidney disease up to a moderate stage (eGFR below 60, up to CKD class 3A), and noticeable nerve damage (Group c)
Healthy volunteers:
- People with no known increased risk of heart or blood vessel disease, matched in age and gender to type 1 diabetes participants
Who may not be able to join:
- People who have difficulty understanding the participant information due to a cognitive impairment
- People who have difficulty understanding the participant information due to a language barrier
- People who currently have an active infection or inflammatory condition
- People who are pregnant or breastfeeding
- People who have damaged or scarred tissue in the body areas being examined by the study devices
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Sarah Tehrani, MD, PhD, Danderyd Hospital, Department of Internal Medicine, Stockholm, Sweden
Phone: +46703169040
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Correlation between investigational device-derived energy in endothelial band and endothelial pathology; Correlation between investigational device-derived energy in the myogenic band in the case of hypertension and myogenic related pathology; Correlation between investigational device-derived energy in the neurogenic band and indication of neuropathy; Correlation between investigational device-derived brachial post-occlusive hyperemia (PORH) peak oxygenation and degree of neuropathic angiopathy; Difference in response (perfusion) to mild local heat provocation between diabetes type 1 and heal...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.